/
INAB
$1.43+$0.07 (+5.15%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$13.0M
10M shares
52-week range
$1.17 – $2.73
17% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
3.77%
Moderate
Price (6 mo)
Loading chart…
Change$-298.57
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $96.0K | $96.0K | $0 | $0 | $0 | $2.5M | $0 | $2.5M |
| Gross profit | −$96.0K | −$96.0K | $0 | $0 | $0 | −$2.5M | $0 | −$2.5M |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $581.0K | $2.4M | $5.4M | $7.3M | $14.1M | $16.8M | $17.0M | $10.2M |
| Operating income | −$2.0M | −$5.1M | −$8.6M | −$14.7M | −$28.5M | −$30.3M | −$30.4M | −$19.9M |
| EBITDA | −$2.0M | −$5.0M | −$8.5M | −$13.9M | −$27.4M | −$27.5M | −$26.9M | −$16.9M |
| Net income | −$2.1M | −$5.1M | −$8.6M | −$14.7M | −$28.5M | −$30.0M | −$30.4M | −$19.4M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -0.11 | -0.27 | -0.53 | -0.78 | -1.36 | -1.00 | -0.57 | -4.44 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $48M | $-1.24 | $-1.69–$-0.78 | 3 |
| 2027 | $1M | $-1.06 | $-1.06–$-1.06 | 3 |
| 2028 | $11M | $-0.73 | $-1.15–$-0.44 | 3 |
| 2029 | $30M | $-0.91 | $-0.91–$-0.91 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$5.49
Price
$1.43
Implied upside
+284%
Peer comparison
IN8bio, Inc. Common Stock
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
www.in8bio.com- Employees
- 18
- IPO / List date
- Jul 30, 2021
- HQ
- NEW YORK, NY
Held by traders on TradeandTell
No one on the platform currently holds INAB.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in INAB as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-06-06 | 1-for-30reverse |
Recent trades on TradeandTell
No one on the platform has traded INAB yet.
